Plant Name: Piper retrofractum
Taxonomic Information:
Plant ID: NPO6648
Plant Latin Name: Piper retrofractum
Taxonomy Genus: Piper
Taxonomy Family: Piperaceae
Plant External Links:
NCBI TaxonomyDB:
130414
Plant-of-the-World-Online:
683079-1
Used in Medicines:
Country/Region:
Thailand; Indonesia; India; ChinaTraditional Medicine System:
Sowa-Rigpa; TCM; Unani; Ayurveda; SiddhaGeographical Distribution:
Bangladesh; Philippines; Indonesia; India; Cambodia; Vietnam; China; Laos; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| DRD1; CNR2; | |
| GAA; BCHE; ACHE; | |
| TDP1; HPGD; ALDH1A1; SOAT1; | |
| TRPV1; | |
| MAOB; | |
| HIF1A; TP53; | |
| LMNA; RAB9A; NPC1; RAD52; MAPT; MITF; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | SOAT1 | Acyl coenzyme A:cholesterol acyltransferase 1 | P35610 | CHEMBL2782 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | MITF | Microphthalmia-associated transcription factor | O75030 | CHEMBL1741165 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.820E-08 | 4.159E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.519E-07 | 1.371E-03 | BCHE, DRD1, GAA, HIF1A, MAPT, NPC1, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.181E-07 | 1.517E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 1.316E-06 | 3.581E-03 | ACHE, BCHE, CNR2, DRD1 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.608E-06 | 3.891E-03 | ACHE, BCHE |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.372E-06 | 3.973E-03 | BCHE, CYP1A2, DRD1, HPGD, MAOB, NPC1, TP53, TRPV1 |
| MF | GO:0005488; binding | GO:0048037; cofactor binding | 1.904E-06 | 3.973E-03 | ALDH1A1, CYP1A2, CYP2D6, CYP3A4, HPGD, MAOB, SOAT1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.188E-06 | 3.973E-03 | ACHE, BCHE, HPGD, MAOB, MAPT, RAB9A, RAD52, SMN1, SMN2, TP53, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.334E-06 | 4.538E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.821E-06 | 5.595E-03 | CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0097159; organic cyclic compound binding | 7.007E-06 | 7.629E-03 | ALDH1A1, CYP1A2, CYP2D6, CYP3A4, DRD1, HIF1A, HPGD, MAOB, MAPT, MITF, NPC1, RAB9A, RAD52, SMN1, SMN2, SOAT1, TDP1, TP53, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.634E-06 | 9.535E-03 | CYP1A2, CYP3A4 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.053E-04 | 4.255E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 1.243E-04 | 4.750E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.554E-06 | 1.321E-04 | MAOB, CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.160E-05 | 2.870E-03 | CYP1A2, ALDH1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.013E-04 | 2.870E-03 | CYP2D6, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.621E-04 | 7.695E-03 | CNR2, TRPV1, DRD1, TSHR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.136E-03 | 1.610E-02 | MAOB, CYP1A2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.966E-04 | 1.014E-02 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.702E-03 | 2.066E-02 | MAOB, DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 3.156E-03 | 2.682E-02 | MAOB, DRD1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.156E-03 | 2.682E-02 | TP53, HIF1A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.376E-03 | 2.524E-02 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOB; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; MAOB; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| NA: NA | Motor symptoms | NA | MAOB; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; ACHE; DRD1; TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; MAOB; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | MAOB; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
